Professor of Pediatrics, Wayne State University
Pediatric Hematology & Oncology
Dr. Jeanne M. Lusher, MD
|
|
Give Review
Jeanne Lusher practices Pediatric Hematology & Oncology. She went to University of Cincinnati College of Medicine. She over the years received 1 awards: "Super Doctor". Doctor Jeanne M. Lusher, MD is also a published MD. She has 100 paper published. The most recent paper is: Congenital thrombocytopenias.
Publications
- Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.
- Thromboelastography identifies children with rare bleeding disorders and predicts bleeding phenotype.
- Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A.
- Therapeutic and prophylactic ethanol lock therapy in patients with bleeding disorders.
- No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation.
- Emergency department visits in children with hemophilia.
- Development and introduction of recombinant factor VIII - a clinician's experience.
- Von Willebrand factor mutations and new sequence variations identified in healthy controls are more frequent in the African-American population.
- Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.
- Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer.
- Decreased clearance of von Willebrand factor in a patient with type 2B von Willebrand disease following development of immune thrombocytopenia.
- Pediatric reference values for molecular markers in hemostasis.
- Milestones in hemophilia and concepts in future clinical trial design.
- The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.
- Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion.
- First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development.
- Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia.
- Phenotypes of Allo- and Autoimmune Antibody Responses to FVIII Characterized by Surface Plasmon Resonance.
- North American study of factor VIII concentrate potency.
- The National Hemophilia Foundation provides a model of a national blood monitoring system.
- Lack of inhibitor to monoclonal-antibody purified factor VIII concentrate.
- Modern treatment of haemophilia.
- The May-Hegglin anomaly: platelet function, ultrastructure and chromosome studies.
- Macroglobulinemia in a child with acute leukemia.
- Factor VIII concentrates: matching what you see with what you get.
- The incidence of development of irregular red cell antibodies in patients with sickle cell anemia.
- Erythropoiesis in sickle cell anaemia during acute infection and crisis.
- Preoperative exchange transfusion in sickle cell anemia.
- Hematology.
- Assessment of response to treatment and design of clinical trials.
- The hematological aspects of a case of systemic lupus erythematosus.
- Antibody nature of an AHG (factor 8) inhibitor.
- Protocols, dosages and clinical aspects of immune tolerance.
- Congenital disorders affecting platelets.
- Variability in serial CD4 counts and relation to progression of HIV-I infection to AIDS in haemophilic patients. Transfusion Safety Study Group.
- Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
- Controlled clinical trials with prothrombin complex concentrates.
- Hemophilia A in chromosomal female subjects.
- Periodic transfusions for sickle cell anemia and CNS infarction.
- Primary malignant lymphoma cutis in an infant: case report and review of literature.
- New leukemia in the course of therapy of acute lymphoblastic leukemia.
- Exchange transfusion for hyperleukocytosis, anemia, and metabolic abnormalities in leukemia.
- Absence of inhibitory cells from patients with aplastic anemia or transient erythroblastopenia of childhood on the in vitro growth of erythroid colonies.
- Long-term survivors of acute lymphoblastic leukemia--risk of relapse after cessation of therapy.
- Phenotypic change of acute monocytic leukemia to acute lymphoblastic leukemia on therapy.
- Hematological parameters and marrow in vitro colony forming cells in acute lymphoblastic leukemia after cessation of treatment.
- IMFRA (intermittent intrathecal methotrexate and fractional radiation) plus chemotherapy in childhood leukemia.
- Repetitive low-dose radiation therapy for acute stem-cell leukemia.
- High-titer inhibitor development in hemophilia A: lack of product specificity.
- Recombinant clotting factors: a review of current clinical status.
- Recombinant factor VIIa: a viewpoint by Jeanne M. Lusher.
- Intravenous gammaglobulin (Gaminume) for treatment of chronic idiopathic thrombocytopenic purpura (ITP): a two-year follow-up.
- Familial warfarin resistance in a black child.
- Intravenous gamma globulin treatment for chronic idiopathic thrombocytopenic purpura in children.
- Prothrombin complex concentrates in hemophiliacs with inhibitors--a multicenter therapeutic trial.
- Screening and diagnosis of coagulation disorders.
- HIV and hemophilia.
- Transmission of hepatitis C virus by monoclonal-purified viral-attenuated factor VIII concentrate.
- Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee.
- Platelet-vessel-wall interactions: experiences with von Willebrand platelets.
- Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions.
- Transmission of human immunodeficiency virus type 1 by dry-heated clotting factor concentrates. Transfusion Safety Study Group.
- Panel discussion on the treatment of patients with factor VIII inhibitors.
- DDAVP: does the drug have a direct effect on the vessel wall?
- Viral safety and clotting factor concentrates.
- Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status.
- Severe factor VIII and factor IX deficiency in females.
- Acute lymphoid leukemia.
- The problem of therapeutic equivalence with paired qualitative data: an example from a clinical trial using haemophiliacs with an inhibitor to factor VIII.
- The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy.
- The role of prothrombin complex concentrates in the treatment of hemophiliacs with factor VIII inhibitors.
- Systemic causes of excessive uterine bleeding.
- Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study.
- Idiopathic thrombocytopenic purpura in children. The case for management without corticosteroids.
- Infections in leukemic children: a prospective analysis.
- Strategies to promote hemostasis in patients with F VIII inhibitors.
- Current practices regarding newborn intracranial haemorrhage and obstetrical care and mode of delivery of pregnant haemophilia carriers: a survey of obstetricians, neo...
- Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C.
- Open heart surgery in a hemophiliac patient. Hematologic management.
- Clinical trials of the recombinant factor VIII product, Kogenate.
- Factor VIII inhibitors. Etiology, characterization, natural history, and management.
- Ethanol lock therapy for the treatment of catheter-related infections in haemophilia patients.
- Is the incidence and prevalence of inhibitors greater with recombinant products? No.
- Acute idiopathic thrombocytopenic purpura--management in childhood.
- DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.
- Transfusion therapy in congenital coagulopathies.
- Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study.
- Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial.
- Congenital thrombocytopenias.
- Effect of age on human immunodeficiency virus type 1-induced changes in lymphocyte populations among persons with congenital clotting disorders. Transfusion Safety Stu...
- Risk of human immunodeficiency virus type 1 infection among sexual and nonsexual household contacts of persons with congenital clotting disorders.
- Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study.
- Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.
- Prediction and management of adverse events associated with the use of factor IX complex concentrates.
- Management of patients with factor VIII inhibitors.
- Recombinant clotting factor concentrates.
- Low risk for hepatitis C in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. International Study Group.
- Response to 1-deamino-8-D-arginine vasopressin in von Willebrand disease.
- Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors.
Schools
University Of Cincinnati College Of Medicine
George Washington University Med Center
Charity Hospital La Tulane Division
Chld Rsch Center Mich
Tulane University
Washington University
Conditions Treated
- Deep Vein Thrombosis (DVT)
Doctors Specialties
- Pediatric Hematology
- Oncology
Accepted Insurances
Awards
- Super Doctor
Education
-
Louisiana State University -
George Washington University -
University of Cincinnati College of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Alissa M. Martin, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Meera B. Chitlur, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sumita Roy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barbara A. Cushing, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roland L. Chu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Meret Henry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kanta J. Bhambhani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Indira A. Warrier, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bulent Ozgonenel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sureyya Savasan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zhihong J. Wang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Madhvi A. Rajpurkar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rohith Jesudas, MD
This Doctor is OpenDoctor Recommended.
|